title: The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.
abstract: There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.
authors.affiliation: Guy's and St Thomas' NHS Foundation Trust - Diabetes and Endocrinology, St Thomas' Hospital Westminster Bridge Road, London SE1 7EH, UK.
authors.forename: James
authors.initials: J
authors.lastname: Crane
authors.affiliation: Guy's and St Thomas' NHS Foundation Trust - Diabetes and Endocrinology, and King's College London - Diabetes and Nutritional Sciences, London, UK.
authors.forename: Barbara
authors.initials: B
authors.lastname: McGowan
keywords: liraglutide; obesity; pharmacotherapy